Attovia Therapeutics (NASDAQ:ATTO) Releases Earnings Results, Misses Estimates By $0.02 EPS

Attovia Therapeutics (NASDAQ:ATTO) posted its quarterly earnings data on Monday. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02), Zacks reports.

Attovia Therapeutics Price Performance

Shares of Attovia Therapeutics stock traded up $0.69 during trading hours on Monday, reaching $15.96. 325,446 shares of the company’s stock were exchanged, compared to its average volume of 350,522. Attovia Therapeutics has a 52-week low of $12.94 and a 52-week high of $28.00. The company’s fifty day moving average is $18.06. The company has a market capitalization of $728.57 million and a price-to-earnings ratio of -3.27.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ATTO. Citigroup initiated coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set a “buy” rating and a $30.00 price objective for the company. Lifesci Capital began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective on the stock. Leerink Partners assumed coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $52.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Zacks Research raised shares of Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.20.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.